{"id":"diacetylmorphine-injectable","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Overdose risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diacetylmorphine is a semi-synthetic opioid derived from morphine. It crosses the blood-brain barrier more readily than morphine due to its acetyl groups, allowing faster onset of action. Once in the brain, it is deacetylated to morphine and 6-monoacetylmorphine, which activate mu-opioid receptors to modulate pain perception, mood, and reward pathways.","oneSentence":"Diacetylmorphine (heroin) is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and euphoria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:26.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment in opioid-dependent patients)"},{"name":"Severe chronic pain in opioid-tolerant patients"}]},"trialDetails":[{"nctId":"NCT05208697","phase":"NA","title":"Tele-Harm Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-10","conditions":"IV Drug Usage, HIV Infections, Hepatitis C","enrollment":100},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT02324725","phase":"PHASE4","title":"Biomarkers of Injectable Extended Release Naltrexone Treatment","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-10","conditions":"Heroin Dependence, Opioid Dependence","enrollment":32},{"nctId":"NCT01999946","phase":"PHASE4","title":"Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-06-27","conditions":"Heroin Dependence, Opioid-Related Disorders","enrollment":217},{"nctId":"NCT02700217","phase":"NA","title":"Does Adding Spinal Anaesthesia to a General Anaesthetic Technique Influence Readiness for Discharge in Patients Having Hand Assisted Laparoscopic Live Donor Nephrectomy","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2016-03-16","conditions":"Surgery","enrollment":101},{"nctId":"NCT03604861","phase":"","title":"An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-08","conditions":"Opioid-use Disorder, Opioid-related Disorders","enrollment":534},{"nctId":"NCT02537574","phase":"PHASE3","title":"Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-08","conditions":"Opioid Use Disorder","enrollment":380},{"nctId":"NCT03557632","phase":"NA","title":"University of Houston Drug Abuse Research Development Program II","status":"UNKNOWN","sponsor":"University of Houston","startDate":"2014-08-01","conditions":"Heroin Dependence","enrollment":100},{"nctId":"NCT00476242","phase":"PHASE2, PHASE3","title":"Memantine as a Supplement to Naltrexone in Treating Heroin Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-06","conditions":"Opioid Dependence, Heroin Dependence","enrollment":82},{"nctId":"NCT01556425","phase":"PHASE2","title":"The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-05","conditions":"Opioid Dependence","enrollment":84},{"nctId":"NCT00577408","phase":"PHASE3","title":"Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opiate Dependence, Heroin Dependence","enrollment":60},{"nctId":"NCT00678418","phase":"PHASE3","title":"ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2008-06","conditions":"Opiate Dependence","enrollment":250},{"nctId":"NCT02598856","phase":"PHASE1","title":"Bioavailability of Nasal Naloxone and Injected Naloxone Compared","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-03","conditions":"Drug Overdose","enrollment":22},{"nctId":"NCT00198861","phase":"","title":"Neurobehavioral Model of HIV in Injection Drug Users","status":"COMPLETED","sponsor":"The City College of New York","startDate":"2002-02","conditions":"Drug Abuse, HIV Infections","enrollment":836},{"nctId":"NCT01447212","phase":"PHASE3","title":"Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-12","conditions":"Opioid Dependence, Heroin Dependence","enrollment":202},{"nctId":"NCT02733822","phase":"PHASE1","title":"Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study","status":"UNKNOWN","sponsor":"King's College London","startDate":"2016-06","conditions":"Drug Overdose, Opioid-Related Disorders","enrollment":4},{"nctId":"NCT01723527","phase":"PHASE1","title":"Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-12","conditions":"Cocaine-Related Disorders, HIV, Heroin Dependence","enrollment":1},{"nctId":"NCT01831284","phase":"","title":"Correlates and Consequences of Increased Immune Activation in Injection Drug Users","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2012-12","conditions":"Intravenous Drug Usage","enrollment":201},{"nctId":"NCT01471145","phase":"PHASE4","title":"Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-01","conditions":"Opioid-Related Disorders, Heroin Dependence","enrollment":40},{"nctId":"NCT00175357","phase":"PHASE3","title":"NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-03","conditions":"Opiate Addiction","enrollment":192},{"nctId":"NCT01931332","phase":"NA","title":"Intrathecal Diamorphine Versus Femoral Nerve Block in Primary Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2010-02","conditions":"Osteoarthritis","enrollment":120},{"nctId":"NCT01912573","phase":"PHASE4","title":"Nasal Naloxone for Narcotic Overdose","status":"UNKNOWN","sponsor":"Judith Feinberg","startDate":"2013-09","conditions":"Drug Overdose","enrollment":236},{"nctId":"NCT00332228","phase":"PHASE2","title":"Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2002-06","conditions":"Opiate Dependence","enrollment":125},{"nctId":"NCT00241943","phase":"NA","title":"A Video-Based HCV Curriculum for Active Injection Drug Users","status":"COMPLETED","sponsor":"Organization to Achieve Solutions in Substance Abuse (OASIS)","startDate":"2005-11","conditions":"Hepatitis C, Opiate Dependence","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Diacetylmorphine, injectable","genericName":"Diacetylmorphine, injectable","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diacetylmorphine (heroin) is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and euphoria. Used for Opioid use disorder (maintenance treatment in opioid-dependent patients), Severe chronic pain in opioid-tolerant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}